

Company Number: 211291

European Institute of Women's Health Limited
Annual Report and Financial Statements
for the financial year ended 30 June 2023

European Institute of Women's Health Limited

CONTENTS

	Page
Directors and Other Information	3
Directors' Report	4 - 10
Directors' Responsibilities Statement	11
Independent Auditor's Report	12 - 13
Income and Expenditure Account	14
Balance Sheet	15
Reconciliation of Members' Funds	16
Cash Flow Statement	17
Notes to the Financial Statements	18 - 20

European Institute of Women's Health Limited

DIRECTORS AND OTHER INFORMATION

Directors	Maeve Cusack Barbra Dowling Janusz Janczukowicz Meryam Schouler-Ocak Heidi Siller
Company Secretary	Cl's Company Secretary Limited (Appointed 22 May 2023) Hilary Murphy (Resigned 22 May 2023)
Company Number	211291
Charity Number	20035167
Registered Office	Ashgrove House Ashgrove Industrial Estate Kill Avenue Dun Laoghaire Dublin
Auditors	Only Audit Limited Chartered Certified Accountants & Statutory Auditors 56 Lansdowne Road Ballsbridge Dublin 4
Bankers	Bank of Ireland 2 College Green Dublin 2
Solicitors	Young & Company 2 Charleston Road Rathmines Dublin 6

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2023

The directors present their report and the audited financial statements for the financial year ended 30 June 2023.

Principal Activity and Review of the Business

The objective of the European Institute of Women's Health (EIWH) is to promote the advancement of education and public awareness of women's and family health issues throughout Europe by conducting research, undertaking surveys, establishing and delivering training programmes, seminars and conferences on all aspects of health care. The EIWH is a registered charity (number 20035167) and is governed by a board of directors. Membership of the EIWH is open to individuals and organisations with an interest in women's and family health. EIWH has a membership base of individuals and organisations that contribute to the ongoing work of the EIWH. <http://www.charitiesregulatoryauthority.ie/en/cra/pages/home>

Together with its members, the EIWH works to:

- Promote lifelong health in women and their families.
- Ensure quality and equity in health policy, research, treatment and care for all.
- Draw the attention of policymakers to the obstacles that women who belong to minority and disadvantaged groups face in obtaining a desirable health status.
- Empower individuals to play an active part in their own health management.
- Promote gender-specific biomedical and socioeconomic research that addresses sex and gender-based differences, to ensure equal access to quality prevention, treatment and care for women and their families throughout their lifespan. The EIWH aims to reduce inequalities in health, those due to gender, age and socioeconomic status, by highlighting that sex and gender are important determinants of health. The EIWH works to improve and promote the understanding that vulnerability to, onset and progression of specific diseases vary in men and women.

Key priorities of the EIWH include:

- Prevention of chronic diseases.
- Promotion of health and well-being and combating smoking and obesity in women.
- Promoting active and healthy ageing across the lifespan and increasing healthy life years.
- Ensuring access to high quality treatment and care across an individual's lifespan.
- Ensuring safety of medicines in pregnancy and lactation.
- Highlighting sex and gender in medicines regulation and medical education.
- Promoting vaccination across the lifespan.
- Advocating for healthy pregnancies.
- Advocating for awareness of mental health issues, with a focus on managing depression.
- Advocating for sex and gender sensitive health systems.

The EIWH has an Expert Advisory Group appointed by our Board which guides EIWH policies and activities.

Board Members:

- Maeve Cusack, National Cancer Control Programme, Ireland
- Barbara Dowling, University of the Arts London, UK
- Janusz Janczukowicz, Lodz University, Poland
- Meryam Shouler-Ocak, Charite, Germany
- Heidi Siller, Universität Klagenfurt, Austria

Secretariat

- Peggy Maguire, Director General
- Vincent Herity, Financial Manager
- Vanessa Moore, Senior Researcher
- Rebecca Moore, Senior Researcher
- Aoibhinn Collery, Research and Communications Officer joined in November 2022

Board Activity

Members of the board of the EIWH are located Europe-wide therefore a bi-monthly meeting is hosted on Zoom. The meetings provide the opportunity to present, review and evaluate the activity undertaken by the EIWH as well as agree an outline of the future activity, direction and priorities for the EIWH.

Financial Overview

One of the main objectives of the board is to ensure the sustainability of the EIWH. The main source of income for the EIWH is through EU project funding. This is supplemented from time to time by industry funding. The EIWH continues to apply for project funding while examining further opportunities to diversify.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2023

Governance

The EIWH initiated the review of its governance code to ensure compliance with the statutory Irish Governance Code for charities. The compliance form has been completed and will be submitted to the charity regulator for review upon acceptance initial review and acceptance from the board.

Activity Overview 2022 – 2023

Advisory Roles

The EMA

The EIWH has been a member of the Patient and Consumer Working Party (PCWP) of the European Medicines Agency for the last 20 years. The Working Party provides recommendations to EMA human scientific committees on all matters of interest to patients and citizens in relation to the safe and effective use of medicinal products. The European Medicines Agency is the European Union (EU) body responsible for the scientific evaluation and approval of medicines developed by pharmaceutical companies. The EMA centrally reviews and approves innovative medicinal products, based on the clinical trial data supplied by the applicant organisation. This approval process is strictly defined and regulated by EU legislation. Once approved, the medicinal product receives a marketing authorisation for use in the EU and European Economic Area (EEA). The EIWH is a member of EMA Geriatric Expert Group and the EMA working group of Clinical Trials Results for Laypersons.

European Centre for Disease Control and Prevention (ECDC)

The EIWH is a member of the Technical Advisory Group on Vaccination. The EIWH attended the technical advisory group for a number of years giving the patient perspective, communicating the efficacy of vaccinations and trying to increase uptake.

The EIWH is also a member of ECDC Advisory Forum Representing patients. During COVID there were meetings every month due to the extent of issues to be discussed.

European Commission DG SANTE

The EIWH has been a member of Health Technology Assessment Stakeholder Pool for the JA EU-NET-HTA since the beginning of the legislation the commission introduced, in an advisory capacity. The EIWH highlights the gender perspective and communicates this to the group. The EIWH also produced a position paper on gender and health technology assessment.

As a member of the DG SANTE Joint Action on Vaccination Stakeholder Network, the EIWH gives the patient and the gender perspective on vaccination and the issues around research, education and communication.

European Patients Forum (EPF)

The EIWH is a member of two working groups: the Digital Health Working Group and the Universal Access to Healthcare Working Group.

The [Digital Health Working Group](#) will contribute to developing EPF's overall strategy in digital health, including work towards the gathering of patients' views on various topics related to digital health, including the protection and sharing of data from patients' electronic health records.

In its work it will take into account EPF's ongoing work on health data, including the work within the IMI project, the European Health Data Network (EHDEN); issues emerging from the IMI ADAPT SMART project on real-world evidence; and the implementation of the EU Data protection Regulation (GDPR) from the health governance perspective. The group will also inform EPF membership on technical topics through briefings.

The group will take a lead on specific activities as defined by its members in an annual work plan or as requested by the EPF Board or Secretariat. Position documents developed by the group will be subject to a consultation of the full membership before their formal adoption.

The [Universal Access to Healthcare Working Group](#) is working towards developing a vision of what constitutes a high-quality, safe, equitable and sustainable healthcare system from the patient perspective. The working group informs, guides and supports EPF's work on Universal Health Coverage and Access to healthcare from both a strategic and content perspective, in order to support EPF's broader membership, Board and the Secretariat in this work. The working group will work towards the implementation of the EPF Roadmap to achieving universal health coverage for all by 2030, using it as a guide and reference. The group will take a lead on specific activities as defined by its members in an annual work plan.

The EIWH is a part of the [Label to Enable](#) Advisory Board. This verifies the safety and accuracy of information on patient health and wellness applications. The project focuses on three pillars: trust, use and adoption.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2023

The EIWH is a member of COMPAR-EU. This group focuses on four chronic diseases. In 2022 the EIWH wrote an article for COMPAR-EU titled, [the Gender Perspective and Self-Management Interventions on Chronic Diseases: Diabetes, Obesity, COPD and Heart Failure](#). This was published on their website and disseminated on social media channels.

European Public Health Alliance (EPHA)

The EIWH is a Board Member and a former President of the EPHA.

The World Health Organisation

The EIWH has been working with the WHO as an external consultant since 2000, with a focus on gender mainstreaming. In partnership with the WHO Academy Quality Committee Board, the EIWH is leading the Patients and Community of Interest Group, creating action plans, organising meetings and liaising with stakeholders in each of the WHO regions. The Patient and Communities of Interest Working Group will support the WHO Academy Quality Committee by advising, supporting and co-creating learning modules for healthcare workers across the WHO Regions as defined in the WHO Charter.

Women's Health Taskforce

The EIWH is a co-chair of the [Women's Health Taskforce](#). The EIWH supported the establishment of a Women's Health Task Force in the Department of Health in Ireland. This is made up of members of the Department of Health as well as from other government departments, the Health Service Executive, the National Women's Council of Ireland, the Institute of Public Health, healthcare professionals and many others. The taskforce was developed to improve women's health outcomes and the experiences of women in the healthcare setting, and to create new initiatives in coherence with existing policies to progress women's health nationally. The inclusion of women's voices across the life course was central to this project, including both positive and negative experiences of the healthcare system. The social determinants of health were also considered to ensure marginalised and minority women were included and considered. The taskforce performs radical listening exercises, listening to and engaging with women and women's organisations across Ireland. This is an example of open policymaking.

Ireland's first Women's Health Action Plan was published as a result of the taskforce. This was launched by the Minister for Health. This plan sets out women's priorities for health as specified by women and women's organisations. The action plan includes a strategic framework for the progress of women's healthcare, identifying gaps in the service, improving women's experiences in the healthcare system and accounting for vulnerable and marginalised groups to improve the standard of care for all. This was accompanied by further public investment in women's health.

The taskforce hosts 'Women's Health Weekly'. This is a forum which brings together experts and advocates to speak on important issues that affect women's health. This sparks debate, discussion and knowledge-sharing.

Women in Global Health

The EIWH sits on the Advisory Board for [Women in Global Health Ireland](#). This is a group of individuals who represent academia, private sector and non-governmental organisations coming together to support gender equality in global health leadership.

Research Projects

CONCEPTION

[CONCEPTION](#) is a project aiming to generate and disseminate reliable evidence-based information regarding effects of medications used during pregnancy and breastfeeding to women. The overall role of the EIWH is to bring the voice of women as (future) mothers, patients and family carers to the research project. The EIWH participates in the dissemination and education process for healthcare professionals, pregnant and breastfeeding women and the general public; cross-stakeholder engagement; information and data governance; and scientific coordination, project management & sustainability.

IDEAHL

[IDEAHL](#) stands for Improving Digital Empowerment for Active Healthy Living. The ultimate purpose of the project is to empower EU citizens in using digital tools to have a more active role in the management of their own health and well-being, as well as supporting social innovations for person-centred care models.

The EIWH is involved in the gender and inclusion aspects for the co-design, development and implementation of the strategy. Equality and digital accessibility are fundamental for IDEAHL targeted groups, especially those who are at risk of exclusion from the digital world. The EIWH conducted a scoping review of the gender and inclusion aspects in digital health literacy and the relevant policy documents, as well as hosting two workshops on IDEAHL and digital health literacy. Actions will be done based on the EU Digital Principles and the Skills Agenda. The EIWH chaired a meeting on Gender, Ethics and Digital Health literacy.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2023

SPIOMET4HEALTH

[SPIOMET4HEALTH](#) is a clinical trial testing a novel treatment for adolescent girls and young adult women with Polycystic Ovary Syndrome (PCOS) that tackles the root of the problem rather than masking symptoms.

The EIWH's role in the project is to develop the tools and materials for project communication and dissemination activities and in patient engagement. The EIWH also contributed to creating awareness among key stakeholders of the need to address PCOS in broader health promotion and disease prevention programmes due to the high prevalence and under-diagnosis of the condition. The EIWH created a series of blogs in partnership with Make Mothers Matter as well as the clinical trial information for potential participants.

CBIG SCREEN

The [CBIG-SCREEN](#) project aims to reduce inequality by improving access to cervical cancer screening for vulnerable and underserved groups.

EIWH is the lead on communications and social media. The EIWH has co-hosted a webinar with Sirpa Pietikäinen (MEP) in the EU Parliament; produced content including interviews with various stakeholders including policymakers; hosted a Roundtable in the EU Parliament with Tilly Metz (MEP); created the newsletter and numerous podcasts.

Upcoming Research Projects

REAL4REG

Regulatory and health technology assessment (HTA) agencies, academic institutions and patient organisations from six EU countries will improve the use of real-world data (RWD) in regulatory decision-making under a new project funded by the Horizon Europe Programme.

The Real4Reg project stands for development, optimisation and implementation of artificial intelligence methods for RWD analyses in regulatory decision-making and HTA along the product lifecycle.

The EIWH is involved in the gender perspective in all the work packages and the communication and dissemination strategy.

Policy Briefs

The EIWH has a series of policy briefs. These are short but comprehensive documents on specific health or disease related topics. They provide an overview of the current state of play with regard to women's health and present findings and recommendations aimed at a non-expert audience. They raise awareness on the gender differences in health.

The full list of policy briefs, which were updated in 2022, are available on the EIWH website and are regularly promoted on the organisation's Twitter account. They are available in English, and one policy brief thus far, on women and vaccination, is available in 7 European languages. Policy briefs include Women and AIDS/HIV; Women and Breast Cancer in the EU – A Life Course Approach; and Women and Diabetes in the EU, among many more. There are 29 policy briefs in total and the full list can be found [on our website](#).

Research Reports

Midlife and Older Women's Health

A report on Midlife and Older Women's Health was commissioned and published by the EIWH. This was launched in 2022 at a Roundtable discussion hosted by Sirpa Pietikäinen (MEP). This will be further disseminated in 2023.

Maternal Health

A EIWH report titled, 'Maternal Health in the EU' was launched at a Roundtable in 2022 hosted by Deirdre Clune (MEP). A panel of experts at the event included the EU Commission, the WHO, the EU Midwives Association and the EIWH Advisory Board on Maternal Health. This report will be promoted through the EIWH online platforms and at the EIWH events.

A Lifetime of Caring – Who Cares?

The 'A Lifetime of Caring – Who Cares?' Report will be launched in 2023. The report highlights the central issues surrounding women's caring roles across the life course from rearing children to caring for young, elderly, disabled or sick family members. Lack of resources, decision-making power and unfair work divisions have large repercussions and opportunity costs for women and girls. In support of the EU Caring Strategy (2022), the EIWH will use the recommendations to develop an EIWH Advisory Group, which will include Age Platform, EUROCARERS and Alzheimer's Europe Age Platform on older women's health. Again, this report will be distributed to the European Commission, the European Parliament and other key stakeholders, whilst also promoting it widely on the EIWH media outlets and at the upcoming conference on Women's Health.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2023

Maternal Health in the EU launched in 2023

- A lifetime of caring: who cares? In partnership with EUROCARERS launched
- Endometriosis Policy Brief initiated
- Scoping Review of Young Women's Health initiated
- Mapping of Models of Good Practice in EU started

EU Consultations

The EIWH has responded to the following:

- EU Commission Roadmap on Access to Vaccination
- EU Commission Roadmap on Violence against Women
- Consultation EU Beating Cancer Roadmap
- Consultation EU Pharma Strategy
- EU Commission Gender Equality Strategy
- New EMA Regulatory Strategy
- WHO workplan 2021-2027
- EU4Health Programme 2021-2025
- European Public Health Alliance Consultation on EU4Health

Meetings and Webinars

The EIWH organised, hosted, chaired, spoke at, attended and participated in a wide variety of meetings and webinars. These included:

- As part of the CBIG Screen project, the EIWH organised and co-hosted a webinar and a roundtable on Cervical Cancer with MEs in the EU Parliament.
- For the Irish Global Health Network Conference, the EIWH with Ailbhe Smyth, an Irish activist co-chaired the Women in Global Health workshop on Leadership.
- Organised a Roundtable in the EU Parliament on the Maternal Health Report. This was co-hosted by Deirdre Clune (MEP).
- Chaired a webinar on digital health literacy as part of the IDEAHL consortium.
- The Midlife and Older Women's Health Report was launched at a Roundtable in the EU Parliament, organised by the EIWH and hosted by Sirpa Pietikäinen (MEP).
- Attended the EFPIA Patient Think Tank contributing to discussions on patient engagement. The EIWH also attended the EU Health Summit: Towards an EU Health Union
- Chaired a meeting on health inequalities for Women Political Leaders
- Partner with ECDC and EMA European Immunisation week
- Speaker for the event titled, 'Addressing Gender related issues and bias in the Prevention and Treatment of Neurological Conditions' in the EU Parliament.
- Partner with EMA and ECDC in European Antibiotic Awareness Day digital launch event
- Speaker at RSV roundtable.
- As a member of the Independent Patient Safety Council, the EIWH attended meetings.

EIWH Strategy 2020 – 2025

- The EIWH promotes an equitable, sex and gender-sensitive approach to health policy, research, treatment and care
- Prioritising women's health in all EU policy, programming and funding mechanism
- Establishing a Women's Health Interest Group in the European Parliament
- Increasing the evidence and advocacy base for women's health issues through publications and social media
- Partnering with EU organisations, efforts and activities
- Capacity-building by expanding EIWH communications and network membership

The Company is limited by guarantee not having a share capital.

There has been no significant change in these activities during the financial year ended 30 June 2023.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2023

Principal Risks and Uncertainties

The company operates solely in the Republic of Ireland. Therefore, it is not subject to significant currency risks. The company does not rely on significant borrowings and has a minimal exposure to interest rate risk. The company is a not for profit company that relies on the funding it receives from various organisations. The principal risk to the company is the risk of reduced funding.

The company's policy is to ensure that sufficient resources are available to ensure all obligations can be met as they fall due.

The directors are aware of the major risks to which the company is exposed, in particular those related to the operations and finances of the company and are satisfied that systems are in place to mitigate exposure to major risks.

Financial Results

The surplus/(deficit) for the financial year amounted to €16,356 (2022 - €(28,467)).

At the end of the financial year, the company has assets of €282,551 (2022 - €177,532) and liabilities of €275,527 (2022 - €186,864). The net liabilities of the company have decreased by €16,356.

Directors and Secretary

The directors who served throughout the financial year were as follows:

Maeve Cusack
Barbra Dowling
Janusz Janczukowicz
Meryam Schouler-Ocak
Heidi Siller

The secretaries who served during the financial year were:

CIs Company Secretary Limited (Appointed 22 May 2023)
Hilary Murphy (Resigned 22 May 2023)

The company is limited by guarantee not having a share capital and therefore the directors or company secretary have no direct interest in the company.

In accordance with the Articles of Association, the directors retire by rotation and, being eligible, offer themselves for re-election.

Future Developments

The company plans to continue its present activities and current trading levels. Employees are kept as fully informed as practicable about developments within the business.

Post Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

Auditors

The auditors, Only Audit Limited, (Chartered Certified Accountants & Statutory Auditors) have indicated their willingness to continue in office in accordance with the provisions of section 383(2) of the Companies Act 2014.

Statement on Relevant Audit Information

In accordance with section 330 of the Companies Act 2014, so far as each of the persons who are directors at the time this report is approved are aware, there is no relevant audit information of which the statutory auditors are unaware. The directors have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and they have established that the statutory auditors are aware of that information.

European Institute of Women's Health Limited

DIRECTORS' REPORT

for the financial year ended 30 June 2023

Accounting Records

To ensure that adequate accounting records are kept in accordance with sections 281 to 285 of the Companies Act 2014, the directors have employed appropriately qualified accounting personnel and have maintained appropriate computerised accounting systems. The accounting records are located at the company's registered office at Ashgrove House, Ashgrove Industrial Estate, Kill Avenue, Dun Laoghaire, Dublin.

Signed on behalf of the board

Barbra Dowling
Director

Maeve Cusack
Director

Date: _____

Date: _____

European Institute of Women's Health Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2023

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the surplus or deficit of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and surplus or deficit of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014 and enable the financial statements to be readily and properly audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board

Barbra Dowling
Director

Date: _____

Maeve Cusack
Director

Date: _____

INDEPENDENT AUDITOR'S REPORT

to the Members of European Institute of Women's Health Limited

Report on the audit of the financial statements

Opinion

We have audited the financial statements of European Institute of Women's Health Limited ('the company') for the financial year ended 30 June 2023 which comprise the Income and Expenditure Account, the Balance Sheet, the Reconciliation of Members' Funds, the Cash Flow Statement and the related notes to the financial statements, including the summary of significant accounting policies set out in note 2. The financial reporting framework that has been applied in their preparation is Irish Law and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", issued in the United Kingdom by the Financial Reporting Council, applying Section 1A of that Standard.

In our opinion the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 30 June 2023 and of its surplus for the financial year then ended;
- have been properly prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard; and
- have been properly prepared in accordance with the requirements of the Companies Act 2014.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are described below in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of financial statements in Ireland, including the Ethical Standard for Auditors (Ireland) issued by the Irish Auditing and Accounting Supervisory Authority (IAASA), and the Provisions Available for Audits of Small Entities, in the circumstances set out in note 4 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report other than the financial statements and our Auditor's Report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

In our opinion, based on the work undertaken in the course of the audit, we report that:

- the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Directors' Report have been prepared in accordance with applicable legal requirements.

We have obtained all the information and explanations which, to the best of our knowledge and belief, are necessary for the purposes of our audit.

In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records.

INDEPENDENT AUDITOR'S REPORT

to the Members of European Institute of Women's Health Limited

Matters on which we are required to report by exception

Based on the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the requirements of any of sections 305 to 312 of the Act, which relate to disclosures of directors' remuneration and transactions are not complied with by the Company. We have nothing to report in this regard.

Respective responsibilities

Responsibilities of directors for the financial statements

As explained more fully in the Directors' Responsibilities Statement set out on page 11, the directors are responsible for the preparation of the financial statements in accordance with the applicable financial reporting framework that give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, if applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operation, or has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (Ireland) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the IAASA's website at: www.iaasa.ie/wp-content/uploads/2022/10/Description_of_auditors_responsibilities_for_audit.pdf. The description forms part of our Auditor's Report.

The purpose of our audit work and to whom we owe our responsibilities

Our report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume any responsibility to anyone other than the company and the company's members, as a body, for our audit work, for this report, or for the opinions we have formed.

Tracey Byrne

for and on behalf of

ONLY AUDIT LIMITED

Chartered Certified Accountants & Statutory Auditors

56 Lansdowne Road

Ballsbridge

Dublin 4

Date: _____

European Institute of Women's Health Limited

INCOME AND EXPENDITURE ACCOUNT

for the financial year ended 30 June 2023

	Notes	2023 €	2022 €
Income		261,469	96,119
Expenditure		(245,113)	(124,586)
Surplus/(deficit) for the financial year		<u>16,356</u>	<u>(28,467)</u>
Total comprehensive income		<u><u>16,356</u></u>	<u><u>(28,467)</u></u>

Approved by the board on _____ and signed on its behalf by:

Barbra Dowling
Director

Maeve Cusack
Director

European Institute of Women's Health Limited

BALANCE SHEET

as at 30 June 2023

	Notes	2023 €	2022 €
Current Assets			
Cash and cash equivalents		282,551	177,532
Creditors: amounts falling due within one year	8	(275,527)	(186,864)
Net Current Assets/(Liabilities)		7,024	(9,332)
Total Assets less Current Liabilities		7,024	(9,332)
Reserves			
Income and expenditure account		7,024	(9,332)
Equity attributable to owners of the company		7,024	(9,332)

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

Approved by the board on _____ and signed on its behalf by:

Barbra Dowling
Director

Maeve Cusack
Director

European Institute of Women's Health Limited
RECONCILIATION OF MEMBERS' FUNDS

as at 30 June 2023

	Retained surplus/	Total
	€	€
At 1 July 2021	19,135	19,135
Deficit for the financial year	<u>(28,467)</u>	<u>(28,467)</u>
At 30 June 2022	(9,332)	(9,332)
Surplus for the financial year	<u>16,356</u>	<u>16,356</u>
At 30 June 2023	<u>7,024</u>	<u>7,024</u>

European Institute of Women's Health Limited

CASH FLOW STATEMENT

for the financial year ended 30 June 2023

	Notes	2023 €	2022 €
Cash flows from operating activities			
Surplus/(deficit) for the financial year		16,356	(28,467)
		16,356	(28,467)
Movements in working capital:			
Movement in creditors		88,663	(8,939)
Cash generated from/(used in) operations		105,019	(37,406)
Net increase/(decrease) in cash and cash equivalents		105,019	(37,406)
Cash and cash equivalents at beginning of financial year		177,532	214,938
Cash and cash equivalents at end of financial year	7	282,551	177,532

European Institute of Women's Health Limited

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 30 June 2023

1. General Information

European Institute of Women's Health Limited is a company limited by guarantee incorporated in Ireland. Ashgrove House, Ashgrove Industrial Estate, Kill Avenue, Dun Laoghaire, Dublin is the registered office, which is also the principal place of business of the company. The nature of the company's operations and its principal activities are set out in the Directors' Report. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the year ended 30 June 2023 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Income

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	15% Straight line
----------------------------------	---	-------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Taxation

No charge to current or deferred taxation arises as the company has been granted charitable status under Sections 207 and 208 of the Taxes Consolidation Act 1997, CHY number 12184.

3. Departure from Companies Act 2014 Presentation

The directors have elected to present an Income and Expenditure Account instead of a Profit and Loss Account in these financial statements as this company is a not-for-profit entity.

European Institute of Women's Health Limited

NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 30 June 2023

4. Provisions Available for Audits of Small Entities

In common with many other businesses of our size and nature, we use our auditors to assist with the preparation of the financial statements.

5. Employees

The average monthly number of employees, including directors, during the financial year was 4, (2022 - 2).

	2023 Number	2022 Number
Administration	4	2

6. Tangible assets

	Fixtures, fittings and equipment €	Total €
Cost		
At 1 July 2022	18,741	18,741
At 30 June 2023	18,741	18,741
Depreciation		
At 1 July 2022	18,741	18,741
At 30 June 2023	18,741	18,741
Net book value		
At 30 June 2023	-	-

7. Cash and cash equivalents

	2023 €	2022 €
Cash and bank balances	282,551	177,532

8. Creditors Amounts falling due within one year

	2023 €	2022 €
Taxation	17,692	28,107
Other creditors	13,322	-
Accruals	30,825	36,657
Deferred Income	213,688	122,100
	275,527	186,864

9. Status

The liability of the members is limited.

Every member of the company undertakes to contribute to the assets of the company in the event of its being wound up while they are members, or within one year thereafter, for the payment of the debts and liabilities of the company contracted before they ceased to be members, and of the costs, charges and expenses of winding up, and for the adjustment of the rights of the contributors among themselves, such amount as may be required, not exceeding € 2.

European Institute of Women's Health Limited
NOTES TO THE FINANCIAL STATEMENTS

for the financial year ended 30 June 2023

10. Capital commitments

The company had no material capital commitments at the financial year-ended 30 June 2023.

11. Controlling interest

The company is controlled by the directors.

12. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

13. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on _____.